-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Achieves Outstanding Results in the Provincial Mass Quality Management Achievement Evaluation
Category:
发布时间：2025-10-29
【概要描述】
Recently, the results of the 2025 Hebei Provincial Mass Quality Management Activities Awards were announced. Four problem-solving and innovation-oriented project outcomes submitted by the QC teams of Shijiazhuang No.4 Pharmaceutical Group were commended by the judging panel for their significant practical value and innovative nature. All four quality-related scientific and technological achievements entered in the competition received awards—three first prizes and one second prize—demonstrating the group’s solid foundation and remarkable achievements in quality management.
Recently, the results of the 2025 Hebei Provincial Mass Quality Management Activities Awards were announced. Four problem-solving and innovation-oriented projects submitted by the QC teams of Shijiazhuang Sihua Pharmaceutical Group were recognized by the judging panel for their significant practical value and innovative nature, with all four entries receiving awards—three first prizes and one second prize—thereby highlighting the group’s solid foundation and remarkable achievements in quality management.
These award-winning achievements are closely aligned with business operations and management, focusing on resolving critical quality issues and enhancing process technology. Specifically, three projects—“Investigating the Detection Accuracy of Soft-Bag Light Inspection Machines,” “Improving the Light Inspection Rate on Production Line 24#,” and “Enhancing the 12-Hour Dissolution of Nifedipine Sustained-Release Tablets (II)” —were awarded First-Class Quality Science and Technology Achievements; while the project “Developing a New Method for Quality Control of Small-Volume Injectable Preparations” was recognized as a Second-Class Quality Science and Technology Achievement. These accomplishments embody the collective wisdom and hard work of frontline employees and the quality management team, vividly demonstrating the positive role that QC groups play in quality improvement.
As a leading enterprise in the pharmaceutical industry, the Group has consistently upheld the principle of “quality first” and is committed to the research, development, and production of high-quality “Made-in-China medicines.” In recent years, the company has proactively benchmarked against internationally advanced quality management systems, fostering deep integration between quality philosophy and manufacturing practices. Notably, in the area of pharmaceutical quality risk management, it has innovatively implemented the “21235 Risk Management Model Based on Parameter Release,” shifting the focus of quality control from end-product testing to critical stages of the manufacturing process. This approach enables proactive early warning and precise control of quality risks, and the model has been recognized as a typical case of quality improvement and brand building by the Ministry of Industry and Information Technology (in the category of quality technology innovation and application) and as a recipient of the “Quality Management Craftsmanship Achievement” award from the China Pharmaceutical Quality Management Association.
Meanwhile, the Group has continuously organized mass quality-improvement initiatives such as “Quality Month,” “Quality Year,” “Small Improvements and Innovations,” and “Rationalization Proposals,” as well as QC team problem-solving activities, thereby fostering a robust quality culture in which every employee cares about, values, and strives for quality.
According to reports, the mass quality management initiative in Hebei Province is organized and implemented by the Hebei Provincial Quality Association. It serves as a widely influential, province-wide platform for grassroots quality innovation, aimed at fostering an advanced quality culture, motivating enterprises to pursue continuous improvement, and providing robust support for advancing the strategy of building Hebei into a province strong in quality.
A relevant official from the group stated, “We will earnestly carry out QC team problem-solving activities, continuously promote the organic integration of quality management and technological innovation, fortify the lifeline of the enterprise’s high-quality development, and make due contributions to the building of a Healthy China.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091